NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 5 May 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair Topics 2 & 3) Present for all items
2. Dr Lindsay Smith (Chair Topic 1) Items 1 to 6.1.3
3. Martin Bradley Present for all items
4. Dr Matt Bradley Items 5 to 6.2.2
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Items 1 to 6.1.3
7. Chris Herring Present for all items
8. Dr Andrew Hitchings Present for all items
9. Dr Robert Hodgson Present for all items
10. Dr Bernard Khoo Present for all items
11. Ivan Koychev Items 1 to 6.2.1
12. Dr Soo Fon Lim Present for all items
13. Dr Guy Makin Present for all items
14. Professor David Meads Items 1 to 5.1.2
15. Giles Monnickendam Present for all items
16. Dr Malcolm Oswald Present for all items
17. Professor Chris Parker Items 1 to 4.2.2
18. Dr Rebecca Payne Present for all items
19. Carole Pitkeathley Items 1 to 6.1.3
20. Dr Raju Reddy Present for all items
21. Professor John Watkins Items 5 to 6.2.2

NICE staff present

Jasdeep Hayre, Associate Director Items 1 to 4.2.2 & 6 to 6.2.2

Linda Landells, Associate Director Items 5 to 5.2.2

Gavin Kenny, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Kate Moore, Project Manager Items 5 to 6.1.3

Sally Doss, Heath Technology Assessment Adviser Items 1 to 4.2.2

Victoria Kelly, Heath Technology Assessment Adviser Items 5 to 5.2.2

Lorna Dunning, Heath Technology Assessment Adviser Items 5 to 5.2.2

Christian Griffiths, Heath Technology Assessment Adviser Items 6 to 6.2.2

Alan Moore, Heath Technology Assessment Analyst Items 1 to 4.2.2

Catherine Parker, Heath Technology Assessment Analyst Items 5 to 5.2.2

Thomas Jarratt, Heath Technology Assessment Analyst Items 1 to 5.2.2

Anne Murray Cota, Heath Technology Assessment Analyst Items 1 to 5.2.2

Ziqi Zhou, Heath Technology Assessment Analyst Items 4.1.3 to 4.2.2

Anna Willis, Heath Technology Assessment Analyst Items 5 to 5.2.2

Victoria Gillis-Elliott, Heath Technology Assessment Analyst Items 6 to 6.2.2

Catrin Austin, Technical Analyst, Methods, and economics Items 1 to 4.2.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment, items 5 to 5.2.2

Claire Hawksworth, Technical Analyst, Evidence Generation Items 6 to 6.2.2

Maroulla Whiteley, Business Analyst, RIA Items 1 to 5.2.2

Helen Barnett, Senior Medical Editor Items 5 to 5.2.2

Korin Knight, Senior Medical Editor Items 6 to 6.1.3

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 5 to 5.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Lyn Davis, Coordinator, MIP Items 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Ismahan Abdullah, Administrator, TA Items 1 to 4.2.2 & 6 to 6.1.3

Mohammed Towhasir, Administrator, TA Items 5 to 5.2.2

External assessment group representatives present

Will Sullivan, Peninsula Technology Assessment Group (Pen-TAG), items 1 to 5.1.3

Max Barnish, Peninsula Technology Assessment Group (Pen-TAG), items 1 to 5.1.3

Jeremy Howick, Kleijnen Systematic Reviews Ltd (KSR), items 5 to 5.1.3

Maiwenn Al, Kleijnen Systematic Reviews Ltd (KSR), items 5 to 5.1.3

Emma Knowles, Peninsula Technology Assessment Group (Pen-TAG), items 6 to 6.1.3

Caroline Farmer, Peninsula Technology Assessment Group (Pen-TAG), items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Dr Shobhit Baijal, Consultant Medical Oncologist, Clinical expert nominated by

British Thoracic Oncology Group (BTOG), items 1 to 4.1.3

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, items 1 to 4.2.2

Dr Yvonne Summers, Clinical Director for Medical Oncology, Clinical expert nominated by Royal College of Physicians, items 1 to 4.1.3

Zografia Anastasa, Patient expert nominated by Vasculitis UK, items 5 to 5.1.3

Professor Lorraine Harper, Professor of Nephrology and Honorary Consultant Nephrologist, Clinical expert nominated by Vifor Pharma, items 5 to 5.1.3

Professor David Jayne, Professor of Clinical Autoimmunity, Clinical expert nominated by Vifor Pharma, items 5 to 5.1.3

Dr Peter Lanyon, Consultant Rheumatologist & NHS Commissioning expert nominated by Vasculitis UK, items 5 to 5.1.3

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, items 5 to 5.2.2

Dr Nicholas Torpey, Consultant Nephrologist, clinical expert nominated by the British Transplantation Society, items 6 to 6.1.3

Dr Richard Baker, Consultant in Renal Medicine, clinical expert nominated by, NHS Blood and Transplant, items 6 to 6.1.3

Professor Colin Geddes, Consultant Nephrologist and Honorary Clinical Associate, clinical expert nominated by The Renal Association, items 6 to 6.1.3

Ian Wren, Commissioning expert, NHSE, items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Lindsay Smith welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 7 April 2022.

### Appraisal of atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Roche.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Ivan Koychev declared non-financial professional interests as he has concluded in collaboration with Roche as part of which they developed a digital solution for detecting cognitive deficits in healthy ageing adults. It was agreed his declaration would not prevent Ivan from participating in discussions of this appraisal.
* Committee member Dr Matt Bradley declared financial interests as he holds shares in AstraZeneca, the manufacturer of an identified and participating comparator (Osimertinib). As a direct conflict it was agreed that Dr Bradley would not participate in discussions of this appraisal.
* Nominated clinical expert Dr Shobit Baijal declared financial interests as he has received honoraria from Roche for consultancy work and other pharma companies which are the subject of this appraisal. It was agreed his declaration would not prevent Dr Baijal from providing expert advice to the committee.
* Nominated clinical expert Dr Yvonne Summers declared financial interests as she has participated in paid advisory work for Roche and other pharma companies which are the subject of this appraisal. It was agreed her declaration would not prevent Dr Summers from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Malcolm Oswald, Martin Bradley, and Giles Monnickendam.
  1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10751>

### Appraisal of avacopan for treating anti-neutrophil cytoplasmic autoantibody-associated vasculitis [ID1581]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Vifor Pharma.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Professor Lorraine Harper declared financial interests as she has received speaker fees and a research grant from Vifor Pharma (investigator led study), she has also participated in advisory board for Vifor Pharma and GSK. It was agreed her declaration would not prevent Professor Harper from providing expert advice to the committee.
* Nominated clinical expert Professor David Jayne declared direct financial and non-financial interests as he has received consultancy, lecture fees and clinical research grants from VIfor Pharma. He is clinical director of the Addenbrooke’s Vasculitis Service, Chief Investigator of 11 international randomised trials in vasculitis, and president of the European Vasculitis Society. It was agreed that his declaration would not prevent Professor Jayne from providing expert advice to the committee.
* Nominated clinical and NHS Commissioning expert Dr Peter Lanyon declared direct financial and non-financial professional and personal interests as he is in receipt of a research grant from Vifor Pharma to the University of Nottingham. Dr Lanyon confirmed that Vifor Pharma have had no influence on the design, conduct or interpretation of the research, and that avacopan is not the subject of the research. He is a national clinical co-lead for Rheumatology, GIRFT Programme, NHS England and NHS Improvement, clinical Lead, for National Congenital Anomaly and Rare Disease Registration Service (NCARDRS), Public Health England, co-chair of the Rare Autoimmune Rheumatic Disease Alliance (RAIRDA) and he has co-authored research publications on ANCA-vasculitis. It was agreed that his declaration would not prevent Dr Lanyon from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathley, Dr Ivan Koychev, and Dr Matt Bradley.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10740>

### Appraisal of imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Hansa Biopharma.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Richard Baker declared financial interests as he has received honoraria from Hansa to attend advisory boards. It was agreed his declaration would not prevent Dr Baker from providing expert advice to the committee.
* No further interests were declared for this appraisal
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, all experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10552>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 26 May 2022 and will start promptly at 09.30.